Of the 16 datasets with highly significant changes (P ≤ 0.0001 and |FC| ≥ 2) (Fig. 1b and Supplementary Table S2), 13 (81%) presented lower levels of SMARCA2 transcript in tumor samples than in non-tumor samples. This evidence concerns the gene SMARCA2 and neoplasm.